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OVERALL HYPOTHESIS AND EXPERIMENTAL GOALS 
Inflammation is common to the pathogenesis of a variety of diseases. Persistent 
or excessive inflammation can lead to tissue damage and promote disease in the 
affected tissue. Therapeutics which can regulate and reduce damaging inflammation 
and subsequent disease development are therefore valuable in the treatment of 
inflammation and inflammatory diseases1. 
One commonly used analgesic which has recently been identified as limiting 
inflammation is lidocaine, a known numbing agent that acts by inhibiting sodium ion 
channels2. Additionally, alternative, less toxic therapeutics like snake venom peptides, 
Zep 3 and 4, are thought to have anti-inflammatory effects3. Recent studies have shown 
that lidocaine can attenuate proinflammatory cytokine gene expression and subsequent 
release from microglial cells, the resident macrophages in the central nervous system4–
14. Snake venom peptides have also been shown to reduce cytokine release from 
activated macrophages in part due to reduced gene expression15–17. Yet a well-defined 
mechanism or cellular target for lidocaine or Zep peptides’ anti-inflammatory effects has 
not been proposed.  
The inflammatory response is mediated by the release of cytokines following the 
activation of macrophages or microglial cells. Expression and release of a 





activates the toll-like receptor 4 (TLR4) signaling pathway, and the second signal leads 
to the formation of the inflammasome complex. TLR4 is activated by pathogen-
associated molecular patterns (PAMPS) such as lipopolysaccharide (LPS) or damage-
associated molecular patterns (DAMPS) which result in a cascade of signaling through 
the myeloid differentiation primary response protein 88 (MyD88)-dependent 
pathway18,19. This activation leads to the translocation of the transcription factor, nuclear 
factor kappa B (NF-κB), into the nucleus resulting in the upregulation of the gene 
expression of proinflammatory cytokines such as IL-6 and proIL-1β18,19. A second signal 
such as ATP initiates the assembly of the NLR family pyrin domain containing 3 
(NLRP3) inflammasome complex that activates the protease, caspase-1. Caspase-1 
then cleaves proIL-1β into its mature form allowing it to be secreted from the cell. This 
cytokine and others can then recruit other immune cells causing inflammation18. 
The canonical inflammatory pathway does not indicate a regulatory role for 
sodium ion channels. More broadly, lidocaine is known to non-selectively inhibit cation 
channels3,7. In this context, lidocaine may inhibit ion channels to affect inflammatory 
signaling, reducing the release of IL-1β and other cytokines. For example, ATP-
activated microglial cells have elevated levels of intracellular Ca2+ corresponding to 
increased cytokine release14,19. Lidocaine treatment of the ATP-activated microglial cells 
significantly reduced intracellular Ca2+ concentrations14. Perhaps lidocaine attenuates 




Another related pathway, the mitogen-activated protein kinase (MAPK) pathway, 
responds to stress stimuli to regulate gene expression. These signals include 
fluctuations in intracellular cation concentrations. For example, diminished intracellular 
[Ca2+] signal the MAPK pathway to minimize the response to proinflammatory signals by 
downregulating cytokine gene transcription14,18. Furthermore, NF-κB can also be 
activated by stress stimuli, so both MAPK signaling and NF-κB activation may contribute 
to reduced cytokine secretion19.  
Similarly, snake venom peptides have also been shown to have anti-
inflammatory effects15,16. Like lidocaine, they are classically recognized for their 
analgesic properties15,16. For example, the Neurotoxin-Nna from the venom of Naja naja 
atra has been found to attenuate IL-1β release and inhibit activation of NF-κB15,16. While 
not much is known about Zep peptides specifically, they may have anti-inflammatory 
effects comparable to Neurotoxin-Nna and lidocaine. The goal of this project is to 
understand how lidocaine and Zep peptides act as anti-inflammatory agents on 
activated macrophages.  
Since lidocaine and snake venom peptides have been shown to have anti-
inflammatory effects on inflammatory models through reduced proinflammatory 
cytokine secretion, we hypothesize that lidocaine and Zep peptides also are able 
to exert these effects on macrophages by (1) interacting with a cellular target to 




NF-κB signaling pathways to reduce proinflammatory cytokine expression and 
release. 
 Our first aim was to define how lidocaine attenuates proinflammatory cytokine 
release from macrophages. We hypothesized that lidocaine interacts with an ion 
channel to inhibit the MAPK and NF-κB signaling pathways to reduce proinflammatory 
cytokine release from activated macrophages. The goal was to understand the 
mechanism of how lidocaine reduces macrophage activation. Based on the literature, 
we believed that lidocaine interacts with the cell to inhibit the MAPK and NF-κB 
signaling pathways, reducing gene expression of the cytokines IL-1β and IL-64,5,7–13. 
Less gene expression would result in diminished cytokine secretion. The experiments 
described in Chapter 4 were aimed at determining the mechanism of how lidocaine 
attenuates macrophage activation and subsequent cytokine secretion. 
 Our second aim was to determine if Zep peptides exert an anti-inflammatory 
effect on activated macrophages. We hypothesized that Zep peptides interact with a 
cellular target to inhibit NF-κB activation, decreasing proinflammatory cytokine release. 
The goal was to assess how Zep peptides reduce macrophage activation to attenuate 
the release of inflammatory mediators. Recent literature suggested that snake venom 
peptides exert an anti-inflammatory effect by decreasing NF-κB activation15–17. The 
experiments outlined in Chapter 5 were targeted towards determining if Zep peptides 
reduce macrophage activation by downregulating proinflammatory cytokine gene 




 Chapter 2 will consist of a review of the literature. It will provide an outline of the 
role of inflammation in disease and the disadvantages and advantages of current 
therapeutics to highlight the need for a better understanding of inflammatory pathways. 
The canonical inflammatory pathway will be detailed with special emphasis on activation 
of TLR4 signaling and NLRP3 inflammasome formation. Then lidocaine’s analgesic 
mechanism will be outlined followed by an introduction to the role ion channels play in 
inflammation. It will be followed by a review of local anesthetics and inflammation with a 
focus on lidocaine and snake venom peptides’ activity as an anti-inflammatory. Finally, 















REVIEW OF THE LITERATURE 
Inflammation and Disease 
Acute and Chronic Inflammation. 
 Inflammation is a host defense mechanism of protection against infection or 
injury. The goal of this defense is preventing the spread of a pathogen followed by its 
eradication and subsequent wound healing. First identified around 40 AD by Celsus, the 
cardinal signs of inflammation include swelling, heat, pain, and redness20,21. The 
inflammatory response is mediated by small proteins called cytokines. The IL-1 family 
cytokines are known to cause fever22. 
 Typically, acute inflammation resolves once the initial signal that triggered the 
response is cleared. However, when the signal persists, chronic inflammation is 
induced. Some signals that trigger chronic inflammatory responses include chronic 
infection, unrepaired tissue damage, persistent allergens, and indigestible crystals 
among others23. Chronic inflammation is increasingly a common cause of disease in 
industrialized countries. It is a risk factor that contributes to the cause or complications 
associated with obesity, type 2 diabetes, arthritis, cancer, and neurodegenerative 
diseases23–25. In some cases, the inflammatory response may be causing more damage 





There are many challenges associated with trying to develop drug therapies that 
aim to reduce the inflammatory response. New drug therapies need high specificity and 
high affinity for the target ligand, low toxicity, and high biostability23. None of these ideal 
characteristics are easy to address within the context of inflammation and inflammatory 
diseases. However, they are essential to the development of both safe and effective 
drug therapies. The crux of the problem is that the immune response needs to be tightly 
regulated to ensure that the response is appropriate. Where to draw the line between an 
appropriate and an excessive response is exceedingly difficult. 
Surgery-Induced Inflammation. 
 Not all inflammation is induced in response to an invading pathogen as shown in 
Figure 1. In the absence of an infection, the response is known as sterile inflammation. 
One example is surgery-induced inflammation. Prior to surgery, local anesthetics are 
usually applied topically or injected into the surgical site26. Surgery itself induces a local 
inflammatory response at the site of tissue injury. Local anesthetics like lidocaine have 
been shown to reduce the release of cytokines and chemokines in the acute 
inflammatory response, yet there is still slow resolution of inflammation and the return to 
homeostasis26. Within the context of surgery, local anesthetics may have an added 
benefit; first, they relieve pain at the site of surgery, and later, they may attenuate the 





Figure 1. Causes of Inflammation and Their Pathological Consequences. The three 
inflammatory triggers (infection, tissue injury, and tissue stress and malfunction) induce 
inflammation resulting in a response with potentially pathological consequences. 
Infection is the only activator of inflammation that induces an immune response27. 
 
Treating Inflammatory Diseases 
 Currently, many of the therapies that treat inflammatory diseases aim to minimize 
the symptoms, but they do not prevent progression of the disease28. One drawback of 
these therapies is that there are typically severe side effects with long-term use28. To 
address these disadvantages, a more comprehensive understanding of inflammatory 
pathways is imperative. This approach will fine-tune treatment to minimize side effects 






Protein Anti-Cytokine Drugs. 
 At present, most of the drugs that reduce the production of cytokines are 
proteins29. There are many drawbacks to using protein drugs to treat inflammatory 
diseases29. These drugs have poor stability, poor cellular penetration and cellular 
activity, have short-half lives, are rapidly metabolized, and are expensive to produce29. 
Therefore, it is increasingly important to identify new drugs that have less 
disadvantages to better treat the wide range of inflammatory diseases.  
Small Molecule Anti-Cytokine Drugs. 
 Newer therapies that are being identified or developed to target inflammatory 
pathways are small molecules. These drugs tend to be orally active and are successful 
at targeting proinflammatory signaling pathways in the cell to attenuate the release of 
proinflammatory cytokines without the disadvantages of protein agents29. These small, 
organic molecule therapeutics are likely the most appropriate type to focus on to treat 
inflammatory diseases.  
Canonical Inflammatory Pathway 
 The canonical inflammatory pathway consists of TLR4 signaling activation and 
formation of the NLRP3 inflammasome as shown in Figure 2. Innate immune cells such 
as macrophages respond to infection or tissue injury by releasing proinflammatory 
mediators that include cytokines and chemokines to attract circulating leukocytes to the 
affected tissues23. To initiate the inflammatory response in macrophages, two signals 
are required. The first, priming signal activates TLR4, a transmembrane protein in the 




cytokine gene expression30. The second signal leads to NLRP3 inflammasome 
formation allowing for the cytokine, proIL-1β, to be cleaved into its mature form30.  
Cytokines are then released from the macrophage acting as the inflammatory 
mediators that bridge innate and adaptive immunity. The most common cytokines 
associated with the inflammatory response are TNF, IL-1, IL-6, IL-8, and IL-1023. 
Cytokines such as IL-1β and IL-18 are unique because they don’t use the classic route 
of secretion through the endoplasmic reticulum-Golgi; instead, their immature, 
biologically inactive form that lacks a signal peptide needs to be cleaved for it to be 
released from the cell30,31. Overall, cytokines elicit the inflammatory response as well as 
contribute to the immune response, cell growth, and cell migration23. These small 
molecules facilitate various cellular functions by binding to a cellular receptor to initiate 
downstream signaling cascades23.  
 The first, priming signal is commonly a specific structural feature of a bacterium 
or virus classified as an extracellular pathogen-associated molecular patterns (PAMPs) 
or endogenous stress signals called danger-associated molecular patterns (DAMPs) 
23,24,30,32. These signals interact with pathogen recognition receptors (PRRs) that include 
the Toll-like receptors to activate a signaling cascade23,24,30,32. One common ligand for 
TLR4 is lipopolysaccharide (LPS), which is found on the surface of gram-negative 
bacteria. LPS treatment activates NF-κB to upregulate gene expression of NLRP3 






Figure 2. Canonical Inflammatory Pathway. Two signals are required for upregulation 
and release of proinflammatory cytokines. The first priming signal (LPS binding to 
TLR4) upregulates gene expression of IL-1β and NLRP3. The priming signal 
deubiquitinates NLRP3 and linearly ubiquitinates and phosphorylates the adaptor 
protein ASC to initiate inflammasome assembly. A second signal is then required to 
activate the NLRP3 inflammasome. The four common stimuli for NLRP3 activation 
include relocalization of NLRP3 to the mitochondria, mitochondrial release of ROS, 
mtDNA, and cardiolipin, potassium efflux through the P2X7 receptor, or lysosomal 
destabilization leading to the release of cathepsin. The active NLRP3 inflammasome 
allows caspase-1 to cleave proIL-1β and proIL-18 into their mature forms that can then 
be secreted and mediate the inflammatory response24. 
 
Upregulation of proinflammatory cytokine gene expression is dependent upon 




transcription factor that mediates upregulation of proinflammatory cytokine gene 
expression upon infection or injury, but it also plays a key role in resolution of the 
inflammatory response by upregulating anti-inflammatory genes and genes governing 
apoptosis23. Specifically, the NF-κB subunits p65 and p50 are responsible for its role in 
the inflammatory response23. Several kinases phosphorylate IκBα, the inhibitor of the 
NF-κB subunits p65/p50 that keeps the transcription factor sequestered in the 
cytoplasm23,34. Phosphorylated IκBα is then polyubiquitinated and marked for 
degradation by the 26S proteasome23,34. This step allows for NF-κB to translocate into 
the nucleus where it can bind to the DNA to upregulate inflammatory target genes 
among others23,25,34. 
 A second signal is then required to initiate NLRP3 inflammasome formation. One 
potential signal such as ATP is required to activate the P2X7 receptor, an ATP-gated ion 
channel expressed in monocytes and macrophages35. Concentrations greater than 1 
mM ATP are required for activation of the P2X7 receptor leading to NLRP3 
inflammasome activation and cleavage of proIL-1β into its mature, secreted form35. IL-
1β is then able to recruit other immune cells to initiate an inflammatory response.  
Another cytokine of interest is IL-6. It has a unique role in recruiting neutrophils 
as part of the innate immune response28. As the immune response shifts from innate to 
adaptive, this cytokine initially attracts monocytes and lymphocytes then it assists in the 
resolution of inflammation and tissue repair28. Release of IL-6 is not dependent on 
inflammasome activation because it has a signal sequence that allows it to follow the 




subunits in the case of IL-6 that are worth noting36. For example, transcription of IκBζ is 
induced with LPS activation to specifically bind to the p50 subunit of NF-κB that can 
then associate with the IL-6 promoter36. Therefore, the canonical inflammatory pathway 
is complex, and that the diverse mechanisms that regulate these pathways still need to 
be well-defined. 
Toll-like Receptor 4 Signaling 
 TLR4 is expressed on a variety of different cell types that include macrophages, 
cardiac myocytes, and cells in the CNS37. It can be activated by a variety of well-
characterized exogenous PAMPs and endogenous DAMPs37. As shown in Figure 3, it 
most classically senses LPS, requiring the interaction between TLR4 and myeloid 
differentiation 2 (MD2)37. There is homodimerization of TLR4 that leads to 
conformational changes that recruit the adaptor protein, myeloid differentiation primary 
response protein 88 (MyD88)37. In the absence of MyD88, there is delayed activation of 
NF-κB and MAPK signaling pathways suggesting that the MyD88-dependent pathway is 
necessary for efficient upregulation of proinflammatory cytokine gene expression38.  
Downstream signaling through this pathway leads to activation of transforming 
growth factor β-activated kinase 1 (TAK1)37,39. TAK1 then activates the mitogen-
activated protein kinases (MAPKs), JUN N terminal kinase (JNK), p38, extracellular 
signal-regulated kinases (ERK1/2), and the IκB kinase complex (IKK) that activate the 
transcription factors, NF-κB and activator protein-1 (AP1)37,39. TLR activation results in 
the upregulation of a large number of genes related to antimicrobial defense, metabolic 




genes40. The role that TLR activation plays in infections, inflammation, autoimmunity, 
cancer, and allograft rejection/inflammation is still minimally understood, but it is 
important to understand this pathway for the development of new therapeutics41.  
 
Figure 3. TLR4 Signaling Pathway. Binding of LPS stimulates homodimerization of 
TLR4. MyD88 is then recruited to the TIR domain of the TLR4 dimer. MyD88 recruits 
the IRAKs and TRAF6 to activate TAK1. TAK1 then initiates activation of the MKKs in 
the MAPK signaling pathway and IKK in the NF-κB signaling pathway. The inhibitors of 
the transcription factors, AP-1 and NF-κB, are marked for degradation allowing for 
translocation of the transcription factors into the nucleus. Then there is upregulation of 
proinflammatory cytokine gene expression. The MyD88-independent pathway leads to 










Activation of the NLRP3 Inflammasome 
Mechanism of Activation. 
 Several PRRs such as nucleotide-binding domain, leucine-rich repeat containing 
proteins (NOD-like receptors, NLRs) play a critical role in inflammasome activation by 
sensing signals like DAMPs and PAMPs to upregulate NLRP3 expression and 
contribute to inflammasome activation via other poorly understood mechanisms24,42. 
Part of the response to the priming signal causes deubiquitination of NLRP3 which is a 
fast post-translational modification compared to the more commonly described changes 
in transcription43.  
A variety of disparate but generally accepted mechanisms activate the NLRP3 
inflammasome. These mechanisms include potassium efflux from the cell44, 
relocalization of NLRP3 to the mitochondria, mitochondrial release of ROS, 
mitochondrial DNA, cadiolipin, and cathepsin release from destabilized lysosomes24,45. 
Commonly accepted signals include ATP, pore-forming toxins, crystalline substances, 
nucleic acids, hyaluronan, and fungal, bacterial, and viral pathogens24,30,45. It is 
hypothesized that these diverse signals converge on a point in the signaling pathway to 
induce NLRP3 inflammasome activation24,45. There also is some evidence to suggest 
that an increase in intracellular calcium is associated with inflammasome activation24,45. 
Again, there is controversy regarding how all these signals can initiate inflammasome 
formation.  
Inflammasomes are typically composed of a sensor protein (NLR), an adaptor 




expressed in monocytes and macrophages, so its activity needs to be tightly regulated 
by the inflammasome44,46. The NLRP3 inflammasome can be activated by whole 
pathogens, environmental irritants, or cell-derived signals that indicate cellular damage 
or stress46.  When activated, NLRs form a scaffold that activates caspase-124. Active, 
fully cleaved, caspase-1 which is a protease can then cleave interleukin-1 (IL-1) 
proteins into their mature form to be secreted from the cell24,47. It also can induce 
pyroptosis, a form of inflammation-associated cell death24,47. Pyroptosis occurs through 
swelling of the cytoplasm and rupture of the plasma membrane30.  
To ensure that there is not generally aberrant activation, there are a variety of 
negative regulators in the pathway48. The canonical inflammatory pathways are 
generally mediated by protein kinases and ubiquitin ligases49. Thus, it can be negatively 
regulated by phosphatases and de-ubiquitin ligases49. It has recently been shown that 
among various NLRP3 agonists reducing cytosolic levels of K+ is necessary and 
sufficient to activate caspase-150. Furthermore, an increase in intracellular Na+ 
concentrations contribute to but are not required for inflammasome activation50. As 
evidenced here, there are several examples of the inflammatory pathways being 
activated or regulated by changes in intracellular cation concentrations.  
Role in Disease. 
 In neurological diseases, misfolded protein aggregates and excessive 
accumulation of metabolites act as endogenous DAMPs that lead to activation of the 
NLRP3 inflammasome24. One type of systemic inflammation is caused by missense 




causes the following diseases: familial cold autoinflammatory syndrome, Muckle-Wells 
syndrome, and neonatal-onset multisystem inflammatory disease51. These diseases 
cause recurrent fever, rash, conjunctivitis, and arthralgia51. A better understanding of 
the NLRP3 inflammasome will allow for the development of more effective treatments 
for these diseases. 
 Lidocaine’s Classically Characterized Inhibition of Ion Channels 
Voltage-Gated Sodium Channels. 
Lidocaine is currently used as a local anesthetic, and it prevents ventricular 
arrythmias2. Lidocaine has analgesic effects by inhibiting voltage-gated sodium 
channels (VGSCs) in neurons2. It blocks Na+ from passing through the channel pore2. 
Thus, it prevents membrane depolarization in neurons to keep them from firing in 
response to pain stimuli1. For lidocaine to interact with a VGSC in this manner, the drug 
needs to cross the cell membrane and enter the channel from the cytoplasmic side52. 
Perhaps lidocaine has the same type of interaction with VGSCs expressed in 
macrophages to mediate its anti-inflammatory properties. 
One study analyzed the effect of lidocaine on chemokine release from intestinal 
epithelial cells7. It was hypothesized that lidocaine reduces chemokine release by 
inhibiting VGSCs7. To test this hypothesis, two VGSC agonists that open these 
channels were tested with lidocaine to determine whether the drug inhibits VGSCs in 
this context7. This experimental condition did not affect lidocaine’s reduction in 




inflammatory effect through a mechanism that doesn’t involve VGSCs or that lidocaine 
interacts with the channels in a different way than the two agonists that were used.  
Potassium Channels. 
 In the literature, it has been shown that lidocaine also interacts with potassium 
channels. Predominantly expressed in immune cells, P2X receptors are a class of 
ligand-gated ion channels that are permeable to sodium, potassium, and calcium53. 
Modeled using Xenopus oocytes, lidocaine was shown to inhibit current through ATP-
activated purinergic P2X7. It was found that lidocaine noncompetitively inhibited the 
P2X7 receptor as evidenced by the ATP concentration-response curve53. Additionally, 
the use of two specific agonists for P2X7 were unable to block the activity of lidcaine53. 
Unique to this study, the positively-charged analog of lidocaine, QX-314, was either 
injected into the oocyte or was applied extracellularly to determine whether the target of 
lidocaine was localized on the plasma membrane or localized intracellularly53. 
Interestingly, QX-314 applied extracellularly or intracellularly reduced ATP-induced 
currents53. Thus, lidocaine may act at the plasma membrane in its charged form or it 
may cross the membrane in its uncharged form to also act intracellularly53. There are 
still some open questions regarding how lidocaine interacts with ion channels and the 
effect these different interactions have on the cell.  
Ion Channels and Inflammation 
 In general, ion gradients are essential to healthy cells, and ion fluxes contribute 
to activation of signaling pathways and enzymes43. There is some evidence suggesting 




diseases: diarrheal illness, pyelonephritis, allergy, acute lung injury, and systemic 
inflammatory responses such as septic shock20. The major ion channels that have been 
identified in this role include sodium, chloride, calcium, potassium, transient receptor 
potential, purinergic receptor, and acid-sensing ion channels20. Recently, ion channels 
have become attractive drug targets because they play a critical role in a variety of 
cellular functions54. Currently, approximately 15% of drugs target ion channels to 
ameliorate disease54.  
 In the inflammatory response, when cells are activated by a second signal, ATP, 
there is a change in ionic intracellular concentrations from high K+, low Na+, and low Cl- 
to low K+, high Na+, and high Cl-55. Furthermore, an increase in intracellular Na+ coupled 
with a decrease in intracellular K+ is required for an unidentified step in P2X7 activation 
of caspase-156–58. It has also been shown that release of IL-1β corresponds to an 
increase in intracellular Ca2+ that was released from the ER in conjunction with the 
required ATP-induced K+ efflux for secretion59. Thus, there are a variety of examples of 
changes in ion concentrations affecting activation of the inflammatory response.   
P2X7 Receptor. 
 
 P2X receptors are ion channels found on the plasma membrane that are 
activated by extracellular ATP60. When ATP binds, the P2X pore switches from a closed 
to open conformation that allows for ions to pass through the channel60. When ATP is 
present for long periods of time, there is generation of a large pore in the plasma 




channel22. One study found that pharmacological inhibition of the P2X7 receptor 
attenuated IL-1β release from LPS-activated spinal microglial cells61.  
More recent evidence suggests that NLRP3 activation is connected to fluxes in 
calcium concentration62. When there are elevated extracellular concentrations or 
movement of intracellular reservoirs of calcium into the cytosol, NLRP3 is activated by 
various agonists63–69. When there is a decrease in extracellular Ca2+, there is a 90% 
reduction in IL-1β secretion, but this change has no effect on cleavage of proIL-1β into 
its mature form by caspase-169. Specifically, the role between a decrease in intracellular 
potassium concentration and an increase in intracellular calcium concentrations in 
NLRP3 inflammasome activation has been controversial70. One recent study found that 
an increase in intracellular [Ca2+] was not necessary or required to activate the 
inflammasome in macrophages70. However, many studies were reviewed and showed 
that calcium ion flux does contribute to NLRP3 activation, so it is likely that more work 
needs to be done to address these discrepancies71.  
 Furthermore, bone-marrow derived macrophages (BMDMs) cultured with LPS, 
ATP, and either extracellular Ca2+ or K+ reduced IL-1β secretion63. When LPS-only 
stimulated BMDMs were cultured with Ca2+, IL-1β was secreted in an NLRP3 
inflammasome dependent manner63. NRLP3 activation caused by extracellular ATP has 
been shown to be affected by intracellular Ca2+ signaling65. Furthermore, LPS-
stimulated macrophages secreted fewer cytokines when the large-conductance Ca2+-
activated potassium channel MaxiK was blocked72. Blockade of this potassium channel 




evidence in the literature showing that inhibition of ion channels has an anti-
inflammatory effect on cells.  
Mitogen-activated protein-kinase signaling pathway. 
 
Figure 4. Model of MAPK Signaling Pathway Regulating Ion Channel Expression. 
Inflammatory mediators (IM) activate G-protein coupled receptors on the cell surface to 
initiate a phosphorylation cascade of kinases. Mitogen-activated protein kinase 
activated protein kinase-2 (MAPKAP kinase-2) phosphorylates to inactivate 
tristetraprolin (TTP). TTP then destabilizes ion channel (IC) mRNA by binding to AU-rich 
sequences. MAPKAP kinase-2 can also stabilize TTP mRNA to further contribute to 
degradation of IC mRNA. MAPK can also phosphorylate and activate NF-κB to increase 
IC gene expression20. 
 
 One key pathway that links VGSC and the inflammatory response is the mitogen-




signals including peptide growth factors, cytokines, hormones, and cellular stressors are 
responsible for activating MAPK signaling73. A MAP3K, apoptosis signal-regulating 
kinase 1 (ASK1), is a mediator in both the p38 and JNK signaling pathways73. 
Interestingly, ASK1 is activated by several cellular stressors that include reactive 
oxygen species (ROS), LPS, endoplasmic reticulum stress, and Ca2+ influx73. This 
pathway is known to mediate changes in gene expression and mRNA stability of many 
of the ion channels mentioned as shown in Figure 420. It is also known that p38 MAPK 
signaling contributes to the transcription of TNF-α, IL-1, IL-6, and IL-828. One study 
found that in LPS and ATP stimulated dorsal horn microglial cells there was widespread 
phosphorylation of the p38 MAPK signaling cascade that was associated with IL-1β 
release61. A second study found that by selectively inhibiting the ERK 1/2, JNK, and p38 
MAPK signaling pathways, there was a reduction in IL-1β release from activated cells, 
and the degree of the inhibitor’s effect on cytokine secretion depended on the activating 
signal74. These results suggest that the p38 MAPK signaling pathway is contributing to 
some degree to IL-1β release from activated microglia61. Additionally, when monocytes 
had a 30 min pretreatment with a MAPK inhibitor before LPS activation, there was less 
IL-1β protein present primarily due to less gene transcription75. Additionally, it has been 
shown in the literature that there is phosphorylation in the p38 MAPK signaling pathway 
resulting from activation of both TLR4 and the P2X7 receptor61. Specifically, TLR4 
signaling results in phosphorylation of p38 which contributes to stabilization of the 




reduces the transcription of proinflammatory cytokines has some effect on the MAPK 
signaling pathway.  
Local Anesthetics and Inflammation 
 
Local anesthetics are typically composed of a tertiary amine attached via an 
ester or amide linkage to a substituted aromatic ring76. The classic mechanism of action 
for local anesthetics is preventing Na+ from entering the cell1. This blockade prevents 
membrane depolarization in neurons to prevent them from firing in response to pain 
stimuli1. Local anesthetics act on Na+ channels, K+ channels, Ca2+ channels, transport 
enzymes and phospholipases in excitable cells77–82. One study showed that lidocaine 
had less affinity for Ca2+ channels compared to Na+ channels77. Interestingly, one study 
showed that 1 mM lidocaine blocked the K+ channel TASK-2 from the tandem pore 
domain K+ channels (2P K+ Channels), but the positively charged analog, QX-314 had 
no effect76. The 2P K+ channels are expressed in the CNS, and they regulate the resting 
membrane potential and firing of excitable cells76. The results from these studies 
suggest that lidocaine can interact with a variety of channels but with different affinities. 
This insight will be valuable in our investigation of how lidocaine has anti-inflammatory 
effects on activated macrophages.  
There are two types of anti-inflammatory drugs that are currently available26. 
Classic examples act as enzyme inhibitors or receptor antagonists with more recent 
drugs acting as resolution agonists26. It has been reported that local anesthetics have 




muscle cells and cardiac tissues9. In the future, local anesthetics may be repurposed to 
treat inflammatory diseases.   
Lidocaine as an Anti-Inflammatory Agent 
The literature suggests that local anesthetics such as lidocaine can reduce pro-
inflammatory responses in activated microglia. In general, results from multiple studies 
indicate that lidocaine pretreatment or use as a topical agent has the most anti-
inflammatory effects and improvement in disease models1,83–85. One study addressed 
whether lidocaine can reduce inflammation associated with LPS-induced sepsis in a rat 
model5. They found that there was a reduction in TLR4 and NF-κB expression and IL-6 
release5. These data specifically suggest that lidocaine inhibits the TLR4 MyD88-
dependent signaling pathway by reducing NF-κB translocation into the nucleus5.  
A few in vitro studies have analyzed how lidocaine treatment affects stimulated 
cultured rat or mouse microglial cells. Several types of stimulatory molecules have been 
used. In LPS-only activated cells, the data showed that lidocaine pretreatment reduced 
p38 MAPK phosphorylation, NF-κB inhibitor, IκBα, phosphorylation, and NF-κB 
translocation into the nucleus4. An in vitro model using RAW264.7 murine macrophages 
found a decrease in IL-1β secretion and mRNA expression in LPS and lidocaine treated 
cells33. In TNF-α only activated intestinal epithelial cells, there was a marked reduction 
in the transcription of the inhibitor of NF-κB, IκB, decrease in the degradation of IκBα, 
and a decrease in the translocation of NF-κB into the nucleus7. These results suggest 
that lidocaine may be acting on a target or pathway that is upstream of the activity of the 




cell injury6. This treatment followed by lidocaine reduced pro-inflammatory cytokine 
release. Interestingly, a permanently charged analog of lidocaine exhibited a degree of 
reduction of cytokine production compared to lidocaine, suggesting that lidocaine may 
be interacting with the cell at the plasma membrane6. At physiological pH, lidocaine is in 
both its neutral and positively charged forms, so it can cross the cell membrane or act 
on the cell’s extracellular plasma membrane surface3. It is still unclear what cellular 
target lidocaine has in this context. 
Another study treated rat microglial cells with ATP only. ATP induces formation of 
the NLRP3 inflammasome complex which allows for proIL-1β to be cleaved into its 
mature form in the classical inflammatory pathway, but ATP is also known to induce 
elevated intracellular concentrations of calcium14. In this study, lidocaine treated cells 
had lower concentrations of ATP-induced intracellular calcium as well as decreased 
levels of phosphorylated p38 MAPK and decreased mRNA and protein levels of IL-1β 
and IL-614. Overall, the anti-inflammatory effect of lidocaine has been tested in several 
different cell types and disease models.  
Most of the data in the literature reproducibly shows that lidocaine attenuates 
proinflammatory cytokine release by either downregulation or inhibition of the NF-κB 
signaling pathway in activated microglia or macrophages as well as other cell types4,5,7–
13. Concentrations of lidocaine ranging from 0.2 mM to 20 mM have been shown to 
reduce the secretion of IL-1β (comparable to 50 μg/mL to 5 mg/mL)9. However, there is 
some evidence to suggest that lidocaine treatment of LPS-activated macrophages also 




also showed that lidocaine reduces the occurrence of pyroptosis which is a 
proinflammatory form of cell death33.  
The current literature consistently demonstrates that lidocaine inhibits p38 MAPK 
phosphorylation and NF-κB translocation into the nucleus and that it attenuates pro-
inflammatory cytokine production4–6,14,86. These studies are starting to show pieces of 
lidocaine’s anti-inflammatory effect, but there still needs to be more consensus in the 
field and the proposal of a well-defined mechanism of action.   
Snake Venom Peptides as Anti-Inflammatory Agents 
 Snake venoms have been used as a form of alternative anti-inflammatory 
medicine in China for centuries15,87. This venom contains a diverse set of molecules that 
include toxins, enzymes, and other bioactive factors that have been found to have anti-
tumor, anti-inflammatory, anti-stroke, and analgesic effects15,87. There are several 
studies in the literature that are examining whether these molecules derived from snake 
venom have anti-inflammatory properties and their mechanisms of action15–17. One 
study modeled pulmonary fibrosis in mice using LPS-induced inflammation15. Prior to 
this study, it had been shown that naja naja atra venom (NNAV) or some component of 
it had anti-inflammatory effects in a rheumatoid arthritis mouse model15. NNAV consists 
of several different molecules including a neurotoxin, a cardiotoxin, nerve growth factor, 
phospholipase A2, and cobra venom factor15. Thus, it is difficult to know which specific 
factor is responsible for the anti-inflammatory effects. There was a significant reduction 
in IL-1β and TNF-α found in the serum of animals treated with NNAV compared to 




p65 subunit was translocated from the cytoplasm to the nucleus, yet with NNAV 
treatment there was a significant reduction in NF- κB translocation into the nucleus15. It 
is worth noting that the dose of NNAV used in this study was very small compared to 
the dose injected by a snake bite15. More adverse effects are seen with the dose of a 
snake bite, but significantly lower therapeutic doses can potentially be beneficial with 
reduced side effects15. 
 A second study analyzed the anti-inflammatory effects of a specific peptide 
isolated from Naja naja atra venom. The peptide, neurotoxin-Nna (NT), had previously 
been characterized as an analgesic that binds to the nicotinic acetylcholine receptor to 
block the transmission of the nerve impulse16. This study treated with NT for 1 hr. before 
inducing inflammation with carrageenan, a linear, sulfated polysaccharide found on 
seaweed16. Pretreatment with NT before carrageenan attenuated IL-1β and TNF-α 
release at least in part by a reduction in NF-κB activation16.  
 Another study found that a small peptide isolated from sea snakes has anti-
microbial and anti-inflammatory properties17. They inhibit LPS-induced production of 
TNF-α, IL-1β, and IL-617. It has been found that they act by either directly binding and 
neutralizing LPS or by binding to the TLR4/MD2 complex to prevent homodimerization 
and downstream signaling17. Furthermore, in a murine colitis model, mice were treated 
with a peptide derived from Hydrophis cyanocinctus venom88. Treated mice had 
reduced phosphorylation of IκB and NF-κB activation accompanied by reduced 
phosphorylation of p38, JNK, and ERK1/2 in the MAPK pathway88. It was also found 




of proinflammatory cytokines from activated macrophages89. In treated cells, there was 
decreased MAPK phosphorylation and inhibition of NF-κB activation89.  
While there is little known about the Zep peptides that were used in this study, 
the literature suggests some potential mechanisms of action for the anti-inflammatory 
activity of characterized snake-derived peptides. Finally, recent work demonstrates that 
snake venom peptides can attenuate cytokine release, but it fails to propose a specific 
mechanism for their action or test the effects of peptides on more broadly relevant 
models like human macrophage cell lines.  
Potential Role for Sodium Channels 
Voltage-Gated Sodium Channels. 
 As stated earlier, within the context of pain relief, lidocaine acts on VGSCs to 
prevent sodium ions from passing through the channel2. Lidocaine and other VGSC 
blockers prefer to interact with the ion channel in its inactive state specifically at the α 
subunit52. Sodium channels are expressed in several non-excitable cell types including 
macrophages to contribute to many of the cell’s common functions90,91. There are nine 
different voltage-gated sodium channels (Nav1.1-Nav1.9) that share homologous 
structural elements, but they each have distinct interactions with pharmacological 
agents90,91. Macrophages specifically express TTX-S current, Nav1.5, and Nav1.690. 
There is evidence of upregulation of the sodium channels Nav1.5 and Nav1.6 in various 
disease states in microglial cells91. The use of TTX and phenytoin, toxins that 
specifically bind VGSC, reduce the release of cytokines and chemokines from activated 




and VGSC inhibitors then LPS, there was a reduction in activation of TLR-4, NF-κB, and 
MAPK86. When exploring lidocaine’s anti-inflammatory activity on macrophages, 
voltage-gated sodium channels are unlikely to first come to mind as lidocaine’s most 
likely cellular target. There have been few studies that have first asked the question of 
whether the same ion channels are expressed in neurons as well as macrophages and 
microglia and second whether blocking these specific channels influences the 
inflammatory response.  
 In 2006, Roselli et al. reviewed the role of VGSC blockers as 
immunomodulators52. Electrophysiological recordings have revealed the presence of 
VGSC in microglial cells and macrophages90. Expression of VGSC in non-excitable cells 
fluctuates depending on the state of the cell90,91. Additionally, some studies have shown 
that VGSC specific drugs have reduced the amount of proinflammatory cytokines 
released from microglia90. It has been shown that in microglial cells Na+ flux is 
necessary for their activation because Na+ free media or VGSC blockers inhibited their 
activation. Additionally, this diminished activation is proposed to be due to decreased 
intracellular Na+ concentrations which will affect the exchange of ions through the 
Na+/Ca2+ exchanger14,90,91. If this ion channel has diminished activity, then there will be 
reduced levels of intracellular Ca2+ concentrations which would be associated with 
decreased activation of microglial cells and macrophages by extension14,90,91. As stated, 
stress stimuli such as changes in intracellular Ca2+ concentrations affect the MAPK 
signaling pathway to decrease proinflammatory cytokine gene expression14. Figure 5 




Ion channel activity in cells is complex, and it has diverse effects on the function of cells. 
Further study will need to be done to understand how inhibition of ion channels affects 
the inflammatory response. 
 
Figure 5. Schematic Depicting the Contribution of Sodium Channels to 
Intracellular Ca2+ Concentrations. Depolarization of the microglial cell membrane 
activates the voltage-gated sodium channel (NaV) allowing Na+ to enter the cell. 
Increased intracellular Na+ concentrations reverses activity of the Na+/Ca2+ exchanger 
(NCX) to increase intracellular calcium concentrations. This increase contributes to 
effector functions of the cell. Blockage of Nav with TTX and NCX with KB-R7943 
decreases intracellular calcium concentrations91. [Modified from Persson et al. (2014)]. 
 
Sodium-Hydrogen Antiporter 1. 
 The sodium-hydrogen antiporter 1 (NHE1) is known to be expressed in multiple 
cell types, and there is data to suggest that it contributes to inflammatory responses92. It 
has been shown that inhibition of NHE1 inhibits NF-κB activation and IL-6 production in 
ischemia-reperfusion injury models92. Inhibition of the antiporter also reduced 




of IL-1β and TNF-α from LPS-activated alveolar epithelium by decreased 
phosphorylation of the IκB-α92. Furthermore, in intestinal tract epithelial cells, there was 
a reduction in proinflammatory cytokine release with specific inhibition of NHE1 to 
minimize NF-κB and p38 MAPK activation92. It is possible that lidocaine affects 
leukocytes by changing the intracellular pH by inhibiting the Na+/H+ antiporter93. Here is 
further evidence that another sodium transporter has been connected to the 
inflammatory response, and inhibition of NHE1 attenuates proinflammatory cytokine 
release.  
Potential Role for Calcium Channels 
Store-Operated Calcium Entry. 
 Increases in intracellular calcium concentrations activate lymphocytes specifically 
microglial cells19,91. These changes also contribute to the effector functions of microglial 
cells that include migration and release of cytokines and chemokines to mediate the 
inflammatory response91. Influx of Ca2+ into lymphocytes is primarily mediated by store-
operated calcium entry (SOCE) and calcium-release activated calcium channels 
(CRAC)19. There is constant seepage of calcium ions from the ER that are returned via 
the SOCE mechanism94. Effector functions of microglial cells such as phagocytosis and 
cytokine secretion that are induced by activation with LPS require sustained high 
intracellular concentrations of Ca2+ 19.  
 Additionally, one study conducted by Heo et al. showed that the use of 
pharmacological inhibitors and knockdown of these calcium channels resulted in a 




cells19. Under regular cellular conditions, activity of calcium channels needs to be 
regulated because sustained high intracellular concentrations of Ca2+ cause cell 
death19. Data from this study showed that SOCE activity is required for the release of 
cytokines especially IL-6 from activated microglia19. Overall, the literature suggests that 
calcium channels contribute to activation of the inflammatory response and release of 
proinflammatory cytokines. Here is another potential target for drug anti-inflammatory 
activity. 
Potential Role for Potassium Channels 
 Several studies have found that amide local anesthetics including lidocaine 
interact with K+ channels10. It has been shown that blocking of potassium channels 
inhibits NF-κB activation10. One study found that in myelinated neurons lidocaine 
decreased K+ channel activity by reducing the probability that the channel was in its 
open state95. Lidocaine most likely blocks K+ channels from inside the cell because 
adding the positively charged analog of lidocaine, QX-314, intracellularly blocks channel 
activity to the same extent as lidocaine95. QX-314 applied extracellularly is unable to 
block the pore suggesting that it is necessary for lidocaine to be able to cross the cell 
membrane to act on an intracellular target95. Computer simulations have also found that 
snake venom derived polypeptides can bind to the outer portion of a K+ to block ion 
flow3. Potassium channel blockade is another potential mechanism that anti-







 Recently, therapeutics have been identified for their anti-inflammatory properties. 
These drugs include lidocaine and Zep peptides 3/4. In our model, we plan to test 
whether lidocaine and Zep peptides attenuate proinflammatory cytokine release from 
LPS and ATP activated human differentiated THP-1s. If they do attenuate cytokine 
release, then the primary question will be what is their mechanism of action? There is 
plenty of evidence in the literature that sodium, calcium, and potassium channel activity 
all contribute to some degree to the activation of inflammation. Which channels are 
involved in the anti-inflammatory effect of lidocaine or Zep peptides? Overall, the 
literature lacks a well-defined hypothesis for the mechanism for how these newly 
identified drugs attenuate the inflammatory response. In the following chapters, we will 
address these questions to enrich our understanding of inflammatory pathways: how 














MATERIALS AND METHODS 
Lidocaine Attenuates Proinflammatory Cytokine Release from Activated 
Macrophages 
 
Cell Culture.  
 THP-1s, a human monocyte cell line, were obtained from American Type Culture 
Collection (ATCC). The THP-1 cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 media, supplemented with 10% characterized fetal bovine serum (FBS) 
from Gibco, 100 IU/mL penicillin, 1 mg/mL streptomycin, and 10 ug/mL ciprofloxacin 
hydrochloride. Characterized FBS was used because it has lower levels of endotoxins 
compared to standard FBS to reduce background activation in the following assays. The 
cells were cultured at 37° C with 5% carbon dioxide.  
THP-1 cells were differentiated into macrophage-like cells by treating with 100 
ng/mL phorbol 12-myristate 13-acetate (PMA) for 24 or 48 hrs. The cells rested for 48-
72 hrs before treatment to reduce background activation from PMA differentiation of the 
proinflammatory genes of interest.  
Quantification of IL-1β Secretion by ELISA. 
 THP-1 cells were plated at 500,000 cells per well in a 24-well plate with 100 
ng/mL PMA for 24 hrs to differentiate the monocytes into macrophages. After 





lidocaine hydrochloride for 16 hrs (Sigma-Aldrich). At the end of the pretreatment, some 
wells had a media change, were treated again with 1 mM lidocaine, or previously 
untreated wells were treated with 1 mM lidocaine. Then to activate TLR4 signaling, 10 
ng of LPS was added for 4 hrs. A media change was done then 5 mM ATP was added 
to initiate NLRP3 inflammasome formation. After 3.5 hrs, the supernatant was collected 
from each sample. This experiment was repeated at least three times unless otherwise 
noted.  
In a second set of experiments following the same basic protocol as described 
above, the treatments differed in the following ways: the cells were either pretreated for 
30 minutes with 1 mM lidocaine before the addition of 10 ng LPS, were pretreated for 16 
hrs with 1 mM lidocaine then treated with 1 mM lidocaine before the addition of 10 ng 
LPS or were treated with 5 mM ATP only as a control. LPS treatment was for 4 hrs., and 
ATP treatment was for 3.5 hrs. Then the supernatant was collected. This experiment 
was repeated at least three times unless otherwise noted.  
The samples were analyzed following the manufacturer’s instructions for the 
R&D Systems Human IL-1 beta/IL-1F2 DuoSet ELISA. The plate was read using the 
Gen 5 Plate Reader software. The standard curve was fit with a 4-parameter logistic 
curve. The fit equation was generated and the sample concentrations of IL-1β were 






RT-PCR Analysis of Proinflammatory Cytokine Gene Expression. 
 THP-1 cells were plated at a density of 500,000 cells/well in a 24 well plate with 
100 ng/mL PMA and RPMI media to differentiate the monocytes into macrophages. 
After 24 hrs, the RPMI media was replenished, and the cells rested for 36 hrs. Then the 
cells were treated with 1 mM of lidocaine hydrochloride for 16 hrs (Sigma-Aldrich). 
Some wells had a media change, then 1 mM lidocaine was added immediately prior to 
the addition of 10 ng of LPS in the appropriate wells. After 4 hrs, the media was 
changed, and 5 mM ATP was added in the indicated wells. After 3.5 hrs, the cell lysate 
was collected.  
The RNA was isolated following the manufacturer’s protocol for the Nucleospin 
RNA Plus kit (Macherey-Nagel). The RNA was then reverse transcribed to the 
complementary DNA (cDNA) sequence using an oligodeoxythymidylic acid primer 
following the manufacturer’s protocol (Promega). Real-time PCR (RT-PCR) was 
performed on the cDNA with iTaqTM Universal SYBR® Green Supermix (Bio-Rad). PCR 
was performed at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 
95°C for 30 seconds then 50°C for 1 minute. GAPDH was the housekeeping gene for 
normalization. The primer set used to amplify GAPDH was 5’-
GCACCGTCAAGGCTGAGAAC-3’ for the 5’ primer and 5’-
GCCTTCTCCATGGTGGTGAA-3’ for the 3’ primer. The primer set used to amplify IL-6 
was 5’-GGAGACTTGCCTGGTGAAAA-3’ for the 5’ primer and 
5’ATCTGAGGTGCCCATGCTAC-3’ for the 3’ primer. The primer set used to amplify 




TGGGTAATTTTTGGGATCTACACTCT-3’ for the 3’ primer. The mRNA levels of both 
IL-6 and proIL-1β were normalized to the GAPDH mRNA levels. Fold change in gene 
expression was calculated using the 2-ΔΔCt method was used. 
Statistical Analyses. 
 GraphPad Prism software (GraphPad Software, San Diego, CA) was used to 
conduct the statistical analyses. In most cases a one-way ANOVA was performed using 
the Tukey multiple comparison test (the mean of each group was compared to the mean 
of every other group). All the reported values are reported as mean ± SEM. Each 
experiment was performed at least three times unless otherwise noted.  
Zep 3 and Zep 4 Peptides Attenuate Proinflammatory Cytokine Release from 
Activated Macrophages 
 
Cell Culture.  
 THP-1s, a human monocyte cell line, were obtained ATCC. The THP-1 cells 
were cultured in RPMI 1640 media, supplemented with 10% characterized FBS from 
Gibco, 100 IU/mL penicillin, 1 mg/mL streptomycin, and 10 ug/mL ciprofloxacin 
hydrochloride. Characterized FBS was used for the reasons described above. The cells 
were cultured at 37° C with 5% CO2.  
THP-1 cells were differentiated into macrophage-like cells by treating with 100 
ng/mL PMA for 24 or 48 hrs. The cells rested for 48-72 hrs before treatment to reduce 






Quantification of IL-1β Secretion by ELISA. 
 THP-1 cells were plated at 500,000 cells per well in a 24-well plate with 100 
ng/mL PMA for 24 hrs to differentiate the monocytes into macrophages. After 
approximately 36 hrs, the differentiated macrophages were pretreated with 12 ug/mL 
Zep 3 or 50 ug/mL Zep 4 for 16 hrs (Dr. Bruce Gaynes, Loyola University Chicago). At 
the end of the pretreatment, some wells had a media change, were treated again with 
12 ug/mL Zep 3 or 50 ug/mL Zep 4, or previously untreated wells were treated with 12 
ug/mL Zep 3 or 50 ug/mL Zep 4. Then to activate TLR4 signaling, 10 ng of LPS was 
added for 4 hrs. A media change was done then 5 mM ATP was added to initiate 
NLRP3 inflammasome formation. After 3.5 hrs, the supernatant was collected from each 
sample. The samples were analyzed following the manufacturer’s instructions for the 
R&D Systems Human IL-1 beta/IL-1F2 DuoSet ELISA. The plate was read using the 
Gen 5 Plate Reader software. The standard curve was fit with a 4-parameter logistic 
curve. The fit equation was generated and the sample concentrations of IL-1β were 
predicted using the Gen 5 Plate Reader software.    
RT-PCR Analysis of Proinflammatory Cytokine Gene Expression. 
 THP-1 cells were plated at a density of 500,000 cells/well in a 24 well plate with 
100 ng/mL PMA and RPMI media to differentiate the monocytes into macrophages. 
After 24 hrs, the RPMI media was replenished, and the cells rested for 36 hrs. Then the 
cells were treated with 12 ug/mL Zep 3 or 50 ug/mL Zep 4 for 16 hrs (Dr. Bruce Gaynes, 
Loyola University Chicago). Some wells had a media change, then 12 ug/mL Zep 3 or 




appropriate wells. After 4 hrs, the media was changed, and 5 mM ATP was added in the 
indicated wells. After 3.5 hrs, the cell lysate was collected.  
The RNA was isolated following the manufacturer’s protocol for the Nucleospin 
RNA Plus kit (Macherey-Nagel). The RNA was then reverse transcribed to the 
complementary DNA (cDNA) sequence using an oligodeoxythymidylic acid primer 
following the manufacturer’s protocol (Promega). Real-time PCR (RT-PCR) was 
performed on the cDNA with iTaqTM Universal SYBR® Green Supermix (Bio-Rad). PCR 
was performed at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 
95°C for 30 seconds then 50°C for 1 minute. GAPDH was the housekeeping gene for 
normalization. The primer set used to amplify GAPDH was 5’-
GCACCGTCAAGGCTGAGAAC-3’ for the 5’ primer and 5’-
GCCTTCTCCATGGTGGTGAA-3’ for the 3’ primer. The primer set used to amplify IL-6 
was 5’-GGAGACTTGCCTGGTGAAAA-3’ for the 5’ primer and 
5’ATCTGAGGTGCCCATGCTAC-3’ for the 3’ primer. The primer set used to amplify 
proIL-1β was 5’-AATCTGTACCTGTCCTGCGTGTT-3’ for the 5’ primer and 5’-
TGGGTAATTTTTGGGATCTACACTCT-3’ for the 3’ primer. The mRNA levels of both 
IL-6 and proIL-1β were normalized to the GAPDH mRNA levels. Fold change in gene 
expression was calculated using the 2-ΔΔCt method was used. 
Optimized Differentiation of THP-1s into Human Macrophage-like Cells 
Cell Culture.  
 THP-1s, a human monocyte cell line, were obtained ATCC. The THP-1 cells 




Gibco, 100 IU/mL penicillin, 1 mg/mL streptomycin, and 10 ug/mL ciprofloxacin 
hydrochloride. Characterized FBS was used for the reasons described above. The cells 
were cultured at 37° C with 5% CO2.  
THP-1 cells were differentiated into macrophage-like cells by treating with 100 
ng/mL PMA for 24 or 48 hrs. The cells rested for either 24 hrs, 48 hrs, 72 hrs, or 96 hrs 
before treatment to find the optimal time when background activation from PMA 
differentiation is at its lowest. 
Cell Imaging. 
 The cells were imaged after 24 hrs. or 48 hrs. of PMA differentiation. The cells 
were again imaged after 24 hrs., 48 hrs., 72 hrs., and at 96 hrs. of rest following 
differentiation. The changes in morphology at each of these time points was noted. The 
cells were imaged using a confocal microscope.  
RT-PCR Analysis of Proinflammatory Cytokine Gene Expression. 
 THP-1 cells were plated at a density of 500,000 cells/well in a 24 well plate with 
100 ng/mL PMA and RPMI media to differentiate the monocytes into macrophages. 
After 24 hrs. or 48 hrs., the RPMI media was replenished, and the cells rested for 24 
hrs., 48 hrs., 72 hrs., or 96 hrs. The appropriate wells were then treated with 10 ng of 
LPS to upregulate proinflammatory cytokine gene expression. After 4 hrs, the cell lysate 
was collected. 
The RNA was isolated following the manufacturer’s protocol for the Nucleospin 
RNA Plus kit (Macherey-Nagel). The RNA was then reverse transcribed to the 




following the manufacturer’s protocol (Promega). Real-time PCR (RT-PCR) was 
performed on the cDNA with iTaqTM Universal SYBR® Green Supermix (Bio-Rad). PCR 
was performed at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 
95°C for 30 seconds then 50°C for 1 minute. GAPDH was the housekeeping gene for 
normalization. The primer set used to amplify GAPDH was 5’-
GCACCGTCAAGGCTGAGAAC-3’ for the 5’ primer and 5’-
GCCTTCTCCATGGTGGTGAA-3’ for the 3’ primer. The primer set used to amplify IL-6 
was 5’-GGAGACTTGCCTGGTGAAAA-3’ for the 5’ primer and 
5’ATCTGAGGTGCCCATGCTAC-3’ for the 3’ primer. The primer set used to amplify 
proIL-1β was 5’-AATCTGTACCTGTCCTGCGTGTT-3’ for the 5’ primer and 5’-
TGGGTAATTTTTGGGATCTACACTCT-3’ for the 3’ primer. The mRNA levels of both 
IL-6 and proIL-1β were normalized to the GAPDH mRNA levels. Fold change in gene 









LIDOCAINE ATTENUATES PROINFLAMMATORY CYTOKINE RELEASE FROM 
ACTIVATED MACROPHAGES 
Introduction: IL-1β Secretion from Lidocaine Treated Macrophages 
 Recently, local anesthetics such as lidocaine have been identified for their 
potential anti-inflammatory effects on activated macrophages or microglial cells. Within 
the context of pain relief, lidocaine acts on voltage-gated sodium channels2. However, 
the canonical inflammatory pathways including TLR4 signaling and NLRP3 
inflammasome activation do not include a defined role for ion channels aside from 
potassium efflux that initiates inflammasome formation upon ATP activation of the P2X7 
receptor.  
Briefly, several studies have shown that lidocaine attenuates proinflammatory 
cytokine release from macrophages and other cell types in different inflammatory 
disease models4–14. In the literature, various inflammatory stimuli were used, and 
lidocaine treatment reduced cytokine release to different degrees4–14. In one study, 
mouse microglial cells were treated with LPS and IFN-γ to cause endotoxemia and 
subsequent inflammation6. A positively charged lidocaine analog that cannot cross the 
plasma membrane was used6. The data showed a slight decrease in IL-1β release but 
no change in TNF-α from the lidocaine treated cells compared to the positive control6. In 





from LPS-activated and lidocaine treated rat microglial cells4. Additionally, rat microglial 
cells were stimulated with 1 mM ATP only for 2 hrs and lidocaine14. With lidocaine 
treatment, there was a dose-dependent decrease in TNF-α, IL-1β, and IL-614. In 
general, there is some discrepancy in the literature regarding the degree of lidocaine’s 
anti-inflammatory effect on proinflammatory cytokine release. 
Overall, several studies have been done to understand the effect lidocaine has 
on microglial cells and other cell types that have been stimulated by different 
combinations of inflammatory signals. Generally, these studies showed that lidocaine 
treatment attenuated the release of IL-6, TNF-α, and IL-1β. However, none of these 
studies have used a more broadly applicable model human cell line nor have the cells 
been stimulated by both LPS and ATP which are commonly used stimuli of the 
canonical TLR4 signaling and NLRP3 inflammasome activation.  
 Based on the literature and some preliminary experiments, we hypothesized that 
if lidocaine has an anti-inflammatory effect on activated macrophages then there will be 
attenuated release of the proinflammatory cytokine, IL-1β, from these cells. To expand 
upon what is currently known about lidocaine’s anti-inflammatory effect, we used 
differentiated THP-1s which are an immortalized human macrophage-like cell line. 
Additionally, we used both LPS to initially prime the TLR4 MyD88-dependent signaling 
pathway to upregulate the gene expression of proIL-1β. Then ATP was used as the 
second signal to trigger inflammasome complex formation and cleavage of proIL-1β into 




with a priming signal released less than 10% of the IL-1β that had accumulated in the 
cytosol22. In our experiments, we measured IL-1β released in the supernatant after two 
activating signals which gave us higher concentrations of the cytokine release 
compared to other studies.  
The differentiated THP-1s cells were either pretreated with lidocaine for 16 hrs. 
before activation and/or a lidocaine treatment at the time of LPS activation. These 
different timepoints of treatment allow for an understanding of whether there are 
temporal restraints on lidocaine’s anti-inflammatory effect on these cells. If lidocaine 
pretreatment reduces IL-1β release, then the effect will not be directly due to ion flux, 
suggesting a mechanism that affects cellular signaling. In contrast, if lidocaine treatment 
at the time of LPS attenuates IL-1β release, then lidocaine has a rapid, direct anti-
inflammatory effect comparable to its rapid analgesic response. Again, if lidocaine 
diminishes proinflammatory cytokine release, then with lidocaine treatment we would 
expect significantly reduced levels of IL-1β compared to LPS and ATP treatment only.  
Experimental Design: Quantification of IL-1β Release 
 WT THP-1s were plated at a cell density of 500,000 cells/well in a 24 well plate 
with 100 ng/mL PMA to differentiate the cells for 24 or 48 hrs. At this time, the media 
was replaced with fresh RPMI containing Characterized FBS. The cells were then 
allowed to rest for 36 hrs (after 24 hrs PMA differentiation) or 60 hrs (after 48 hrs PMA 
differentiation). Lidocaine (1 mM) was added for the 16 hr pretreatment. After the 
pretreatment, the media was changed in the indicated wells. Then lidocaine (1 mM) was 




changed, and 5 mM of ATP was added to the appropriate wells for 3.5 hrs. Then the 
supernatant was collected to quantify the amount of IL-1β that was released using a 
sandwich ELISA (R&D Systems Human IL-1 beta/IL-1F2 DuoSet ELISA). This 
experiment was repeated at least three times unless otherwise noted. In a second set of 
experiments following the same basic protocol as described above, the treatments 
differed in the following ways: the cells were either pretreated for 30 minutes with 1 mM 
lidocaine before the addition of 10 ng LPS, were pretreated for 16 hrs with 1 mM 
lidocaine then treated with 1 mM lidocaine before the addition of 10 ng LPS or were 
treated with 5 mM ATP only as a control. This experiment was repeated at least three 
times unless otherwise noted.  
Results: Quantification of IL-1β Release 
 To establish if lidocaine has anti-inflammatory effects on activated macrophages, 
we chose to use an overnight pretreatment and a lidocaine treatment at the time of LPS 
addition. This treatment plan allowed for an understanding of whether a pretreatment 
was required or if lidocaine had an immediate effect. When lidocaine acts as a numbing 
agent, its effects are more immediate. In that context, lidocaine directly blocks the 
voltage-gated sodium channels in neurons. This blockade prevents the neuron from 
firing and signaling pain. The question here was whether lidocaine initiates a cascade of 
signaling to minimize an induced inflammatory response over time or does lidocaine’s 
interaction with a cellular target immediately reduce release of proinflammatory 
cytokines. We hypothesized that the drug more likely initiates a change in signaling to 




several signaling pathways. In contrast, the pain response is mediated directly by ion 
channel activity as evidenced by lidocaine’s known blockade of sodium ion flux. 
 As expected, no treatment of differentiated THP-1s resulted in minimal release of 
IL-1β. LPS and ATP treatment caused a significant increase in IL-1β release (Figure 6). 
All lidocaine pretreatments attenuated IL-1β release by approximately a 3-fold reduction. 
Interestingly, the lidocaine pretreatment with a media change before LPS stimulation 
also reduced release of the cytokine. These results suggested that lidocaine causes 
changes in the cell that are still altered at the time of treatment with the proinflammatory 
signals to minimize the response to those stimuli. It was unexpected that a lidocaine 
pretreatment then media change would still affect the responsiveness of the cell to the 
inflammatory signals. A possible explanation is that lidocaine is acting intracellularly and 
was unaffected by a media change. This explanation is also reasonable because at 
physiological pH lidocaine is in both its charged and uncharged forms3. Its uncharged 
form can pass the plasma membrane and act intracellularly in either its positive or 
uncharged form or the charged form can target the cell surface.   
 This experiment also demonstrated that lidocaine treatment at the time of LPS 
addition does not have an anti-inflammatory effect on these cells as evidenced by no 
difference between the amount of IL-1β released from this lidocaine treatment 
compared to the LPS and ATP only control. These results do not support the idea that 
lidocaine has an immediate effect perhaps through direct changes in ion flux to 
attenuate the inflammatory response. The data suggested that changes in ion flux are 




the case where cells were treated with both a lidocaine pretreatment and lidocaine at 
the time of signal 1, there was release of IL-1β comparable to the amount of IL-1β 
released from cells only pretreated with lidocaine. Taken together, the effect on the 
twice lidocaine treated differentiated THP-1s was likely due primarily to the lidocaine 
pretreatment since the lidocaine treatment at the time of LPS did not result in reduced 
cytokine secretion.  
 
Figure 6. Lidocaine Pretreatment Reduces IL-1β Release from LPS and ATP 
Activated Macrophages. Differentiated THP-1s were treated with 1 mM lidocaine 16 
hrs. prior to LPS activation and/or at the time of LPS activation. After 4 hrs., the media 
was changed, and 5 mM ATP was added to the appropriate wells. After 3.5 hrs., the 
supernatant was collected, and an ELISA was performed to measure the amount of IL-
1β secreted. This image was representative of three independent experiments.  
 
 One challenge of working with THP-1s is that there can be a lot of variability in 
responsiveness to stimuli and drug treatment between cell cultures and experiments. To 




experiments with either the 16 hrs. lidocaine pretreatment and treatment at the time of 
LPS or lidocaine treatment at the time of LPS only. Furthermore, the raw maximum 
concentration of IL-1β released from can vary greatly, so here the data are represented 
as fold change in IL-1β secretion. Across experiments, there is a significant reduction in 
IL-1β release from lidocaine pretreated cells, and there is a slight decrease in IL-1β 
release from lidocaine treated cells at the time of LPS. Even with the variability 
associated with THP-1s (discussed further in Chapter 7), lidocaine pretreatment 
significantly attenuated the release of IL-1β to levels comparable to no treatment. Even 
lidocaine treatment at the time of LPS slightly reduces cytokine release which is not as 
evident when looking at the results from only one experiment. Overall, the lidocaine 
pretreatment consistently reduced the amount of IL-1β released to approximately 17 ± 






Figure 7. Lidocaine Treatment Significantly Reduced the Average Fold Change in 
IL-1β Secretion from LPS and ATP Activated Differentiated THP-1s. Differentiated 
THP-1s were treated with 1 mM lidocaine 16 hrs. prior to LPS activation and/or at the 
time of LPS activation. After 4 hrs., the media was changed, and 5 mM ATP was added 
to the appropriate wells. After 3.5 hrs., the supernatant was collected, and an ELISA 
was performed to measure the amount of IL-1β secreted. This graph was representative 
of ten independent experiments. Data were analyzed by one-way ANOVA with Tukey’s 
post-hoc test. Error bars indicated standard error of the mean.  
 
 The 16 hrs. pretreatment raised the question of whether it was lidocaine itself 
that had the anti-inflammatory effect or if it could potentially be a metabolite or some 
other factor that caused reduction in cytokine release. To address this question, cells 
were pretreated with lidocaine for 30 mins. before the addition of LPS and later ATP. 
This timepoint was chosen because in the clinical setting patients receive a lidocaine 
injection approximately 30 mins. before a procedure when numbing is required26. If 




an inflammatory response, then patients who received a lidocaine injection before 
treatment may also have the added benefit of less inflammation as part of the healing 
process and less inflammation-associated pain. Lidocaine may have a dual function of 
providing immediate pain relief during surgery, but also limiting later inflammation 
caused by the tissue injury. 
 The second challenge to be addressed was that proIL-1β is highly expressed in 
untreated differentiated THP-1s. As THP-1s are in culture, we noticed that they have 
increased expression of proinflammatory genes over time. We think these changes 
relate to how sometimes with lidocaine treatment the amount of IL-1β released is more 
comparable to no treatment levels but in other experiments the release is not as 
attenuated. An ATP control only allowed us to appreciate the quantity of IL-1β cleaved 
by ATP that solely depends on basal expression of proIL-1β.  
 The data showed that a 30 min lidocaine pretreatment attenuated IL-1β release 
from activated macrophages to approximately the same degree as the 16 hrs. lidocaine 
pretreatment with a second lidocaine treatment at the time of LPS (Figure 8). Moreover, 
the differentiated THP-1s treated with ATP only released a quantity of IL-1β that was not 
very different from the lidocaine treatment. These results suggested that with a clinically 
relevant lidocaine pretreatment of 30 mins. there were decreased levels of IL-1β 





Figure 8. A Clinically Relevant Lidocaine Pretreatment and an ATP Only Control 
Reduced Release of IL-1β Compared to LPS and ATP Activated Differentiated  
THP-1s. Differentiated THP-1s were treated with lidocaine 30 min. before LPS or 
treated with lidocaine overnight and at the time of LPS. After 4 hrs., the cells were 
additionally treated with ATP or ATP only as a control. After 3.5 hrs., the supernatant 
was collected, and an ELISA was performed to measure IL-1β release. Data were 
analyzed by one-way ANOVA with Tukey’s post-hoc test. Error bars indicated standard 
error of the mean.  
 
Introduction: Quantification of Proinflammatory Cytokine Gene Expression 
 
 To begin to understand the mechanism through which lidocaine attenuated 
release of the proinflammatory cytokine, IL-1β, we decided to quantify the fold change in 
gene expression of IL-6 and proIL-1β. ProIL-1β requires two signals for it to be released 
from the cell. Release of IL-1β requires upregulation of its expression and activation of 
the NLRP3 inflammasome to cleave it into its mature, secreted form. In contrast, IL-6 




It contains a signal sequence that marks it for conventional secretion28. As mentioned 
earlier, proIL-1β is highly expressed in untreated differentiated THP-1s, meaning that 
upon activation with LPS there was a smaller increase in gene expression of this 
cytokine. In contrast, IL-6 is minimally expressed in untreated macrophage-like THP-1s, 
so upon LPS treatment, there is a significant increase in IL-6 gene expression. In these 
experiments, we used two signals to activate these pathways to establish a model in our 
lab that can be used to test a variety of potential anti-inflammatory drugs. Activating the 
differentiated THP-1s with both LPS and ATP will allow us to begin to elucidate 
lidocaine’s mechanism of action. 
 In the literature, a decrease in proinflammatory cytokine gene expression with 
lidocaine treatment accounts for at least part of the reduction in secretion of TNF-α, 
proIL-1β, and IL-68,10. In rat microglial cells stimulated with ATP only, there was a dose-
dependent decrease in gene expression of these cytokines with lidocaine treatment14. A 
second study used LPS only to activate TLR4 signaling, and the data showed that there 
was a decrease in gene expression of TNF-α and proIL-1β with lidocaine treatment4. 
Even though there is some evidence in the literature showing that lidocaine reduces 
proinflammatory cytokine gene expression, the extent of this reduction is rather minimal. 
As a result, perhaps the reduction in gene expression is not the only factor contributing 
to reduced proinflammatory cytokine release.  
Furthermore, in the literature, there are two main pathways that are commonly 
studied in relation to gene expression of proinflammatory cytokines4,14. In the canonical 




transcription factor, NF-κB, into the nucleus where it binds to DNA and upregulates 
gene expression related to several cellular processes18,19. Additionally, the MAPK 
signaling pathway responds to stress stimuli such as changes in intracellular cation 
concentrations to activate downstream transcription factors that also regulate gene 
expression30. If lidocaine acts through a mechanism that inhibits or downregulates these 
pathways, then we would expect reduced gene expression of proIL-1β and IL-6.  
Experimental Design: Quantification of Proinflammatory Cytokine Gene 
Expression 
 
We will again use THP-1s plated at a density of 500,000 cells/well in a 24 well 
plate. They were differentiated with 100 ng/mL of PMA for 24 hrs then allowed to rest for 
36 hrs in fresh RPMI medium. The cells were either pretreated with 1 mM lidocaine for 
16 hrs and/or with 1 mM lidocaine at the time of LPS treatment. The cells were treated 
with 10 ng of LPS for 4 hours then with 5 mM of ATP for 3.5 hrs. The cell lysate was 
collected. Then RNA isolation, cDNA conversion, and RT-PCR were performed on each 
of the samples. These RT-PCR analyses were performed on the same treated cells 
whose supernatant was collected for the previously described ELISA experiments. This 
experimental approach allowed for comparisons to be made between changes in gene 
expression and the amount of protein released. Each experimental condition was 
repeated at least 3 times unless otherwise noted.  
In a second set of experiments, the protocol above was followed, but the 
treatments were different in the following ways: the differentiated THP-1s were 




were pretreated for 16 hrs with 1 mM lidocaine and again with 1 mM lidocaine at the 
time of 10 ng LPS treatment or the cells were treated with 5 mM ATP only for 3.5 hrs. 
Each experimental condition was repeated at least 3 times unless otherwise noted.  
Results: Quantification of Proinflammatory Cytokine Gene Expression 
Our first step towards understanding how lidocaine attenuated proinflammatory 
cytokine release was to measure gene expression for proIL-1β and IL-6. If there was 
less expression of these genes in lidocaine treated cells, we would begin to understand 
one of the contributing factors that accounted for lidocaine’s anti-inflammatory effect on 
human macrophage-like cells. We would expect the fold change in cytokine gene 
expression of lidocaine treated cells to be comparable to no treatment if lidocaine 
inhibited or downregulated the NF-κB and MAPK signaling pathways.  
The fold change in gene expression was normalized to the no treatment 
expression of each of the proinflammatory cytokine genes. There was significant 
upregulation of gene expression of proIL-1β and IL-6 when the differentiated THP-1s 
were treated with both LPS and ATP (Figure 9 A. & B.). There was far greater fold 
increase in IL-6 expression with LPS and ATP treatment compared to proIL-1β. This 
difference was likely due to there being high expression of proIL-1β in untreated 
differentiated THP-1s compared to relatively low expression of IL-6 in these cells. Upon 
activation, IL-6 was more upregulated than proIL-1β due to differences in their basal 
expression.  
In the case of proIL-1β, a 16 hrs. lidocaine pretreatment followed by a media 




decrease in gene expression comparable to no treatment. With the other lidocaine 
pretreatments, there was also a downregulation in proIL-1β, but not to the same extent 
(Figure 9. A.). These results suggested that the reduction in IL-1β release from activated 
macrophages was at least in part due to a downregulation of the cytokine’s gene 
expression. With the lidocaine treatment at the time of LPS, there was no significant 
change in gene expression between that treatment and the LPS and ATP only 
treatment (Figure 9. A.). These data suggested that the changes in IL-1β release from 
activated macrophages was perhaps dependent on lidocaine having time to reach its 
target to initiate downregulation signaling of proinflammatory cytokine gene expression.  
Similar trends were seen with IL-6 gene expression (Figure 9. B.). With the 
lidocaine pretreatments consisting of a 16 hrs. pretreatment and/or a second lidocaine 
treatment at the time of LPS addition, there was a reduction in IL-6 gene expression that 
was comparable across all those treatment groups. Again, lidocaine treatment at the 
time of LPS did not result in a change in IL-6 gene expression compared to the LPS and 
ATP only control. For both genes analyzed by RT-PCR, there was a reduction in gene 
expression with lidocaine pretreatment, but no change in gene expression when 






Figure 9. Lidocaine Pretreatment Reduces Gene Expression of proIL-1β and IL-6 
from LPS and ATP Activated Macrophages. Differentiated THP-1s were pretreated 
with lidocaine for 16 hrs and/or were treated with lidocaine at the time of LPS treatment. 
The macrophage-like cells were treated with LPS for 4 hrs. then ATP for 3.5 hrs. The 
cell lysate was collected. The RNA was isolated, cDNA was made, and RT-PCR was 
performed for each of the samples. These are representative images from at least three 
independent experiments. A. Fold change in gene expression of proIL-1β. B. Fold 





Figure 10. Lidocaine Pretreatment Significantly Reduced the Average Fold 
Change in IL-1β Gene Expression from LPS and ATP Activated Differentiated 
THP-1s. Differentiated THP-1s were pretreated with lidocaine for 16 hrs and/or were 
treated with lidocaine at the time of LPS treatment. The macrophage-like cells were 
treated with LPS for 4 hrs. then ATP for 3.5 hrs. The cell lysate was collected. The RNA 
was isolated, cDNA was made, and RT-PCR was performed for each of the samples. 
This graph was representative of ten independent experiments. Data were analyzed by 
one-way ANOVA with Tukey’s post-hoc test. Error bars indicated standard error of the 
mean. 
 
As described earlier, working with THP-1s can be challenging because there are 
differences in how responsive the cells are between experiments and between cell 
cultures. These challenges were again addressed by averaging the gene expression of 
proIL-1β for the corresponding 10 independent lidocaine experiments that were shown 
in Figure 7. The differentiated THP-1s were treated with either a 16 hrs. lidocaine 
pretreatment and treatment at the time of LPS or lidocaine treatment at the time of LPS 
only. Between experiments, there was a significant reduction in proIL-1β gene 




proIL-1β gene expression from cells treated with lidocaine at the time of LPS (Figure 
10). Overall, the data suggested that lidocaine pretreatment attenuated IL-1β release at 
least in part by reducing this cytokine’s gene expression.  
 Moreover, corresponding to the ELISA data where a 30 mins. lidocaine 
pretreatment and an ATP only control were tested, the cell lysate from those 
experiments was analyzed for changes in proinflammatory gene expression (Figure 11. 
A. & B.). Again, the fold change was normalized for all treatment groups against no 
treatment. With LPS and ATP treatment, there was upregulation of gene expression of 
proIL-1β and IL-6 to roughly the same extent as in the previous set of experiments. 
However, there was no reduction in gene expression of either proIL-1β or IL-6 for the 30 
mins. lidocaine pretreatment or the 16 hrs. lidocaine pretreatment with a second 
lidocaine treatment at the time of LPS addition. These results were somewhat 
surprising, but they suggested that the reduction of IL-1β from lidocaine pretreated 
differentiated THP-1s were likely not solely due to a reduction in cytokine gene 
expression. As expected, there was only minimal upregulation of proIL-1β and IL-6 gene 
expression for the ATP only treatment. These results were consistent with the results of 
the earlier Su et al. study that showed there was marginal upregulation of 
proinflammatory cytokine gene expression in ATP treated cells5. Taken together, these 
data suggested that the reduction in IL-1β release from LPS and ATP activated 







Figure 11. 30 min. Lidocaine Pretreatment and ATP Only Control Have No Effect 
on Proinflammatory Cytokine Gene Expression. Differentiated THP-1s were 
pretreated with lidocaine for 30 mins. or were pretreated for 16hrs and again at the time 
of LPS. The cells were then activated with LPS for 4 hrs. and ATP for 3.5 hrs. In this 
experiment, there was also an ATP only control. The cell lysate was collected. The RNA 
was isolated, cDNA was made, and RT-PCR was performed on all samples. This is 
representative data from one experiment that was performed at least 3 times for all 
treatment groups. A. Fold change in gene expression of proIL-1β. B. Fold change in 







 Our goal was to determine if lidocaine could attenuate proinflammatory cytokine 
release from human macrophage-like cells. Several previous studies have analyzed 
cytokine release from predominantly in vitro or in vivo mouse or rat models4–14. We 
wanted to use a more relevant model in our studies, so we chose the human monocyte 
cell line, THP-1s. We activated differentiated THP-1s with both LPS and ATP to provide 
the two signals necessary for TLR4 signaling and NLRP3 inflammasome formation. The 
use of these two signals in the same experiment was unique to our study. It allowed us 
to begin to determine if lidocaine treatment affected activation of one or both signaling 
pathways. To identify whether lidocaine attenuated proinflammatory cytokine release 
from differentiated THP-1s, we measured IL-1β secretion by ELISA. Additionally, we 
aimed to elucidate the mechanism of lidocaine’s anti-inflammatory effects. We 
measured fold change in gene expression of proIL-1β and IL-6 by RT-PCR to determine 
if lidocaine treatment downregulated cytokine gene expression. Overall, we 
hypothesized that if lidocaine has anti-inflammatory effects on LPS and ATP activated 
human macrophage-like cells, then it would attenuate proinflammatory cytokine release 
by (1) inhibiting a cellular target to decrease intracellular cation concentrations and by 
(2) reducing upregulation of proinflammatory cytokine gene expression mediated by NF-
κB and MAPK signaling.  
 Our data showed that lidocaine pretreatment was required for the most 
significant decrease in IL-1β release compared to LPS and ATP activated cells. 




degree in comparison. The corresponding results for gene expression showed that 
proIL-1β expression was downregulated closer to no treatment levels. Also, between 
experiments, IL-6 expression for lidocaine pretreated cells was downregulated but to a 
lesser extent than proIL-1β. Perhaps there were differences in the degree of the effect 
of lidocaine treatment between genes because proIL-1β is highly expressed in these 
cells so activation by LPS has a lesser effect than it does for IL-6. Furthermore, the 
literature shows that IL-6 expression is regulated by a specific subunit of NF-κB that 
differs from proIL-1β gene upregulation36. Lidocaine pretreatment may not affect 
transcription of these cytokines in the same way.  
 Since our pretreatment was for 16 hrs., the question arose of whether lidocaine 
was being metabolized in that time frame resulting in a metabolite being responsible for 
the effect we saw. We tested a 30 min. lidocaine pretreatment to address this question. 
This length of time is comparable to the amount of time lidocaine is applied before 
surgery26. The results showed that a 30 min. pretreatment was sufficient to attenuate 
cytokine release, but it had no significant effect on cytokine gene transcription. The data 
suggested that downregulation of cytokine gene transcription was only one part of a 
more complex mechanism that contributes to decreased cytokine secretion. Our results 
showed that a clinically relevant pretreatment reduced the production of IL-1β, 
suggesting that patients may experience less surgery-induced inflammation. Further 
studies would be required to identify other ways that lidocaine reduces inflammatory 




 In the second set of experiments, an ATP only control was used to gain a sense 
of how much released IL-1β came from the high basal expression level of proIL-1β. The 
amount of the cytokine found in the supernatant from ATP only treated cells was slightly 
less than the amount released from lidocaine, LPS, and ATP treated cells. The data 
suggested that inflammasome activation and cleavage may still contribute significantly 
to the amount of IL-1β released from lidocaine treated cells. Further experiments 
focusing on NLRP3 inflammasome activation specifically would need to be done to 
identify what effect lidocaine has on inflammasome formation. 
One caveat of these experiments is their variability. Between experiments, 
lidocaine has varying degrees of effect on the amount of IL-1β that is released from 
these activated cells. One possible explanation is that there may be variability in the 
differentiation of the WT THP-1s. Even though the procedure followed is the same each 
time, perhaps the cells from different cultures and from cells with more passages in 
cultures may respond differently to PMA. There is some suggestion in the literature that 
less differentiated cells have a reduced number of ion channels20. If as we hypothesize 
that lidocaine has an ion channel target, then perhaps in less differentiated cells, there 
are fewer targets for lidocaine diminishing its effect. In experiments where we only see a 
marginal effect with lidocaine treatment, those cells may have been less differentiated 
and expressed fewer ion channels to reduce lidocaine’s anti-inflammatory effect.  
A second possibility is that over time in culture these cells express more 
proinflammatory cytokines at the basal level. As the cells become more 




fold change in gene expression between the no treatment and LPS and ATP narrowed. 
Perhaps under these conditions, lidocaine has less of an anti-inflammatory effect. There 
was more fluctuation between experiments in terms of cytokine gene expression, but 
that was likely related to changes in basal expression. Additionally, it was likely that 
lidocaine’s anti-inflammatory effect resulted from other mechanisms besides 
downregulation in proinflammatory cytokine gene expression. Nevertheless, as 
evidenced by the average results from ten experiments, consistent results were seen in 
how much IL-1β secretion decreased from lidocaine treated cells.  
Lidocaine treatment at the time of LPS may not allow sufficient time for lidocaine 
to access its target to reduce cytokine expression and secretion. Okura et al. found that 
when oocytes were treated with lidocaine and ATP at the same time followed by a 
second treatment of lidocaine after 5 minutes there was greater inhibition with the 
second treatment suggesting that there was more time for lidocaine to access its 
target53. The same may be true in our case where treatment of lidocaine immediately 
before LPS may not allow enough time for lidocaine to reach its site of activity before 
inflammation was induced.  
From these experiments, we have shown that lidocaine pretreatment of short and 
long duration attenuated release of IL-1β from LPS and ATP activated differentiated 
THP-1s. This anti-inflammatory effect was partially due to downregulation of 
proinflammatory cytokine gene expression, but it also was likely that other mechanisms 






 The next goal towards understanding lidocaine’s anti-inflammatory activity would 
be to identify the cellular target of lidocaine. The inhibition of several ion channels has 
been shown to reduce inflammatory responses as outlined in Chapter 2. To identify the 
cellular target of lidocaine in this context, we have decided to use RNA-Seq. It is an 
unbiased, global technique that detects all the genes that are either upregulated or 
downregulated by lidocaine treatment compared to the LPS and ATP control. The 
results can be analyzed by organizing the genes in their cellular pathways. The data 
can generate hypotheses about lidocaine’s target and anti-inflammatory mechanism of 














ZEP 3 and ZEP 4 PEPTIDES ATTENUATE PROINFLAMMATORY CYTOKINE 
RELEASE FROM ACTIVATED MACROPHAGES 
Introduction: IL-1β Secretion from Zep Peptide Treated Macrophages 
 In the literature, it has been shown that whole snake venom and peptides 
isolated from the venom have analgesic and anti-inflammatory properties that need to 
be better understood15–17,87. In several in vivo models, there was less IL-1β and TNF-α 
in the serum of animals treated with NNAV or NT before activation of an inflammatory 
response15,16. Peptides derived from snake venom have been used as alternative 
medicines for centuries, but little is known still about how they have anti-tumor, anti-
inflammatory, anti-stroke, and analgesic effects15,87  
 Here, we used Zep peptides derived from snake venom obtained from Dr. Bruce 
Gaynes. We assessed whether the peptides have anti-inflammatory effects on 
differentiated THP-1s activated with both LPS and ATP. We hypothesized that if Zep 
peptides have anti-inflammatory properties like other characterized snake venom 
peptides, then activated macrophages treated with Zep peptides would release less IL-
1β compared to LPS and ATP stimulated macrophages. We followed the same general 
protocol that we used for the lidocaine experiments. Here, differentiated THP-1s were 
pretreated with either Zep 3 or Zep 4 overnight and at the time of LPS or at the time of 





was collected, so that the amount of IL-1β released from these cells could be quantified. 
If Zep 3 or Zep 4 has an anti-inflammatory effect on differentiated THP-1s, then we 
would expect to measure less IL-1β release from peptide treated cells compared to LPS 
and ATP only.  
Experimental Design: Quantification of IL-1β Release  
THP-1s were plated 500,000 cells/well in a 24 well plate. They were 
differentiated with 100 ng/mL PMA for 24 hrs. After 24 hrs., the media was changed, 
and the cells rested for 36 hrs. The appropriate wells were pretreated with either 12 
ug/mL Zep 3 or 50 ug/mL Zep 4 for 16 hrs. Some of the wells were again treated with 
either Zep 3 or Zep 4 before 10 ng LPS treatment. After 4 hrs., the differentiated THP-
1s were treated with 5 mM ATP. After 3.5 hrs, the supernatant was collected to 
measure the concentration of IL-1β that was released. A sandwich ELISA was used to 
quantify the amount of IL-1β that was secreted (R&D Systems Human IL-1 beta/IL-1F2 
DuoSet ELISA). These experiments were repeated more than three times unless 
otherwise noted.  
Results: Quantification of IL-1β Release 
To determine if Zep peptides have anti-inflammatory effects on activated 
macrophages, we first measured the amount of IL-1β released from treated 
differentiated THP-1s. If Zep peptides have an anti-inflammatory effect on activated 
macrophages, then there will be reduction in the amount of IL-1β released from Zep 




With LPS and ATP activation, there was a robust increase in the amount of IL-1β 
released compared to no treatment. The differentiated THP-1s treated with Zep 3 or 
Zep 4 overnight for 16 hrs. and with a second Zep treatment at the time of LPS 
significantly attenuated the release of IL-1β. For cells that were treated with Zep 
peptides only at the time of LPS, there was no difference in the amount of IL-1β 
released compared to the LPS and ATP only control. These results suggested that Zep 
peptide pretreatment does have an anti-inflammatory effect on activated human 
macrophage-like cells as seen by a significant decrease in the amount of IL-1β that was 
secreted.  
 
Figure 12. Quantification of IL-1β Released from Zep 3 and Zep 4 Treated 
Activated Differentiated THP-1s. Differentiated THP-1s were pretreated with Zep 3 or 
Zep 4 for 16 hrs. and/or at the time of LPS stimulation. The cells were then stimulated 
with both LPS and ATP. A sandwich ELISA was used to quantify the amount of IL-1β 
that was released from each condition. This image is representative of at least three 





Introduction: Quantification of Proinflammatory Cytokine Gene Expression 
 Since little was known about these Zep peptides, our experimental plan was 
exploratory. We followed the same approach we took with lidocaine to better 
understand how these peptides attenuated proinflammatory cytokine release. In the 
literature, naja naja atra venom and neurotoxin-nna isolated from the venom have been 
shown to inhibit NF-κB activation15,16. Based on these earlier studies, it would be 
reasonable to hypothesize that Zep peptides may also inhibit NF-κB activation. To test 
this hypothesis, we collected the cell lysate from the earlier ELISA experiments for 
comparison. The RNA was isolated, cDNA was made, and RT-PCR was performed to 
measure changes in proinflammatory cytokine gene expression between Zep peptide 
treated activated cells and LPS and ATP only treated cells. Again, there was a 16 hrs. 
Zep peptide pretreatment with a second treatment at the time of LPS or the cells were 
treated with Zep peptides at the time of LPS only before ATP treatment. Based on the 
literature, if Zep peptides attenuated IL-1β release by inhibiting NF-κB, then we would 
expect to measure downregulation of proinflammatory cytokine gene expression with 
Zep peptide treatment.  
Experimental Design: Quantification of Proinflammatory Cytokine Gene 
Expression 
 
THP-1s were plated at a density of 500,000 cells/well in a 24 well plate. They 
were differentiated with 100 ng/mL of PMA for 24 hrs then allowed to rest for 36 hrs in 
fresh RPMI medium. The appropriate wells were pretreated with either 12 ug/mL Zep 3 




Zep 4 before 10 ng LPS treatment. After 4 hrs., the differentiated THP-1s were treated 
with 5 mM ATP. The cell lysate was collected. Then RNA isolation, cDNA conversion, 
and RT-PCR were performed on each of the samples. These RT-PCR analyses were 
performed on the same treated cells whose supernatant was collected for the previously 
described ELISA experiments. This experimental approach allowed for comparisons to 
be made between changes in gene expression and the amount of protein released. 
Each experimental condition was repeated at least 3 times unless otherwise noted.  
Results: Quantification of Proinflammatory Cytokine Gene Expression 
 To begin to elucidate the anti-inflammatory mechanism of Zep peptides, we 
measured the changes in proinflammatory cytokine gene expression. If Zep peptides 
reduced IL-1β release from activated macrophages by inhibiting NF-κB or other relevant 
transcription factors, then we would expect to measure a decrease in proinflammatory 
cytokine gene expression from Zep peptide treated cells.  
 Similar to the lidocaine results, pretreatment with Zep peptides reduced the 
expression of proIL-1β and IL-6. Zep peptide treatment at the time of LPS addition did 
not significantly affect gene expression, and the cytokine expression levels were 
comparable to the LPS and ATP control. Again, Zep peptide pretreatment had a more 
significant effect on proIL-1β expression compared to IL-6. With Zep peptide 
pretreatment, proIL-1β expression was comparable to no treatment whereas there was 
only a marginal reduction in IL-6 expression. Here, the relative fold change in IL-6 
expression from the positive control compared to no treatment was not in the same 




proinflammatory cytokines. This variability observed between experiments will be 
addressed further in the next chapter. The data suggested that Zep peptides attenuated 
IL-1β release from activated macrophages by downregulating proinflammatory cytokine 
gene expression.  
 
Figure 13. Zep 3/4 Pretreatment Reduced Gene Expression of proIL-1β and IL-6 
from LPS and ATP Activated Macrophages. Differentiated THP-1s were pretreated 
with Zep 3/4 for 16 hrs. and/or were treated with Zep 3/4 at the time of LPS treatment. 
The macrophage-like cells were treated with LPS for 4 hrs. then ATP for 3.5 hrs. The 
cell lysate was collected. The RNA was isolated, cDNA was made, and RT-PCR was 




 A review of the literature showed that snake venom peptides have analgesic and 
anti-inflammatory properties, but well-defined mechanisms of action for these peptides 




TNF-α were measured in the serum of animals treated with NNAV or NT before 
activation of an inflammatory response15,16. In these same studies, NNAV and NT were 
found to inhibit NF-κB activation15,16. It is difficult to draw comparisons between these 
prior studies and our work with Zep peptides. Little prior work has been done with these 
peptides. Specifically, we are not aware of their regular functions. For example, they 
could be enzymes, toxins, or other bioactive molecules which are all commonly found in 
snake venom15,87. Furthermore, it would be difficult to identify a cellular target without 
knowing more about its structure and function. In the literature, it has been shown 
previously that peptides derived from animal venoms inhibited cation channels3. They 
bind extracellularly to the channel and insert a side chain into the selectivity filter to 
prevent ions from passing through the channel3. Perhaps Zep peptides could also 
interact with ion channels to minimize the inflammatory response.  
 In our experiments, we found that Zep peptide pretreatment before LPS and ATP 
activation attenuated IL-1β release, but Zep peptide treatment at the time of LPS had no 
effect. Additionally, we found that Zep peptide pretreatment downregulated expression 
of proIL-1β and IL-6, but Zep peptide treatment at the time of LPS did not affect gene 
expression. The data indicated that Zep peptides were able to reduce an induced 
inflammatory response when applied 16 hrs. prior to LPS and ATP. Less IL-1β was 
secreted due to reduced gene expression. It is possible that other mechanisms 
contributed to Zep peptides’ anti-inflammatory activity. Our studies did not assess the 
effect that Zep peptides have on NLRP3 inflammasome formation or identify potential 




offer a more complete understanding of how Zep peptides diminish inflammatory 



















OPTIMIZED DIFFERENTIATION OF THP-1s INTO MACROPHAGE-LIKE CELLS 
 
Introduction: Optimized Differentiation of THP-1s into Macrophage-Like Cells 
 
 One of the challenges we faced was variability between experiments resulting in 
differences in the degree of the effect lidocaine had on activated differentiated THP-1s. 
We observed varying results between THP-1s in different cultures and differences as 
the cells were in culture for longer periods of time. We noted that based on our qPCR 
data the cells became more proinflammatory over time which corresponded to them 
being less responsive to activation by LPS and ATP. Additionally, we used PMA to 
differentiate the THP-1s into macrophages. PMA activates proinflammatory genes, so it 
was important to allow the cells to rest following differentiation. Longer periods of rest 
allowed for activation by PMA to subside. Thus, we wanted to identify the time point 
when there was a minimum level of background inflammation resulting in a better 
response to LPS and ATP activation.  
 A second factor that was noted was how the morphology of the differentiated 
THP-1s varied depending on how long the cells were treated with PMA and how long 
they rested. We wanted to identify the ideal length of differentiation and rest before 
treating the cells. These conditions should give the most consistently differentiated 
THP-1s to reduce variability between experiments. We were looking for the time point 





cells should be adherent to the plate with a more triangular, pointed morphology 
compared to when they are circular monocytes. Therefore, we aimed to minimize 
differences observed in differentiated THP-1s by optimizing the differentiation process 
to identify when the cells were most responsive to activation by LPS and ATP.  
Experimental Design: Optimized Differentiation of THP-1s into Macrophage-like 
Cells 
 
 WT THP-1s were seeded at a density of 500,000 cells/well in a 24-well plate. The 
cells were differentiated with 100 ng/mL PMA. After 24 or 48 hrs., the media was 
replaced with fresh RPMI. The differentiated cells rested for 24 hrs., 48 hrs., 72 hrs., 
and 96 hrs. At each time point, pictures were taken of the differentiated cells to record 
how their morphology changed over time. After each of the designated periods of rest, 
the cells were treated with 10 ng LPS for 4 hrs. Then the cell lysate was collected. 
Samples were collected for no treatment and LPS treatment for each time point of rest. 
After all samples were collected, the RNA was isolated, cDNA was made, and RT-PCR 
was performed on all the samples. These protocols were executed as described in the 
Materials and Methods section.  
Results: Optimized Differentiation of THP-1s into Macrophage-like Cells 
 First, we wanted to understand how the morphology of differentiated THP-1s 
changed over time after either 24 hrs. or 48 hrs. of PMA differentiation. 
Characterisitcally, when monocytes are differentiated into macrophages, they first have 
a more circular shape when they first adhere to the plate and then over time they have a 




appeared to be more firmly attached to the plate than after onlyl 24 hrs. of PMA 
differentiation (Figure 14). Following 24 hrs. of rest for either group, the cells started to 
have more varied and triangular shape. Based on morphology alone, the cells that were 
differentiated for 48 hrs. before a media change had the most consistent, characteristic 
morphology after 72 hrs. of rest. For both differentiation groups, by 96 hrs. of rest most 
of the cells were floating after a 4 hr. LPS treatment. Again, based on morphology alone 
the cells appeared to have the most characteristic macrophage-like shape after 48 hrs. 
of PMA differentiation followed by 72 hrs. of rest. 
 Next, we measured fold change in gene expression for the proinflammatory 
cytokines, IL-1β and IL-6. In general, cells that were differentiated for 48 hrs. were more 
responsive to LPS treatment as evidenced by greater fold changes in cytokine 
expression compared to no treatment. Furthermore, across conditions, 72 hrs. of rest 
resulted in the greatest upregulation of gene expression with LPS treatment. It is worth 
noting that between 48 hrs. and 72 hrs. of rest the Ct values for proIL-1β increased by 
several cycles after that additional 24 hrs. of rest, meaning that there was less basal 
expression of proIL-1β after more rest. This observation was particularly important in our 
study because we wanted to find conditions that minimized basal expression of 
proinflammatory genes. Overall, the optimal differentiation protocol for THP-1s was 48 
hrs. of PMA differentiation then 72 hrs. of rest before treatment. These conditions 
produced cells that had charactersitic macrophage morphology and were most 





Figure 14. Morphology of 24 or 48 hrs. PMA Differentiated THP-1s. THP-1s were 
differentiated with PMA for either A.) 24 or B.) 48 hrs. Cell images were taken after 24 







Figure 15. Fold Change in Proinflammatory Cytokine Gene Expression of 24 or 48 
hrs. PMA Differentiated THP-1s. THP-1s were differentiated with PMA for 24 or 48 
hrs. The cells were then allowed to rest for 24 hrs., 48 hrs., 72 hrs., or 96 hrs. They 
were activated by LPS for 4 hrs. Then the cell lysate was collected for RNA isolation. 
cDNA was made and RT-PCR was performed for each of the samples. A.) 24 hrs. PMA 
differentiation fold change in IL-1β gene expression. B.) 24 hrs. PMA differentiation fold 
change in IL-6 gene expression. C.) 48 hrs. PMA differentiation fold change in IL-1β 










 Inflammation is commonly associated with the development and progression of 
disease. Chronic or unnecessary inflammation can cause tissue damage which 
contributes to the pathogenesis of disease. Effective therapeutics that target 
inflammatory pathways to minimize excessive inflammation will be valuable in the 
treatment of disease1.  
Since lidocaine and snake venom peptides have been shown to have anti-
inflammatory effects on inflammatory models through reduced proinflammatory 
cytokine secretion, we hypothesized that lidocaine and Zep peptides also were 
able to exert these effects on macrophages by (1) interacting with a cellular target 
to decrease intracellular cation concentrations and by (2) downregulating MAPK 
and NF-κB signaling pathways to reduce proinflammatory cytokine expression 
and release. 
 The literature has shown that lidocaine and snake venom peptides attenuated 
proinflammatory cytokine release from stimulated macrophages, microglial cells, and 
other cell types4,5,14–17,6–13. In our study, we sought to determine whether lidocaine and 
Zep peptides reduced release of IL-1β from LPS and ATP activated human 
macrophage-like cells. Our work has found that pretreatment with lidocaine and Zep 





aimed to begin to characterize the mechanism of lidocaine and Zep peptides’ anti-
inflammatory activity. It has been shown in the literature that lidocaine and snake venom 
peptides inhibit NF-κB and MAPK activation among other mechanisms4,5,14–17,6–13. We 
hypothesized that these anti-inflammatory agents reduced IL-1β release by 
downregulating proinflammatory cytokine gene expression. We found that pretreatment 
with lidocaine and Zep peptides decreased gene expression of IL-6 and proIL-1β. Our 
data suggested that lidocaine and Zep peptides decreased release of inflammatory 
mediators in part due to a decrease in proinflammatory cytokine gene expression 
(Figure 16). Further work needs to be done to identify cellular targets of these 










Figure 16. Model of Lidocaine and Zep peptides’ Anti-inflammatory Activity. LPS 
primes TLR4 to upregulate proinflammatory cytokine and NLRP3 gene expression. ATP 
is the second signal that activates the P2X7 receptor to initiate NLRP3 inflammasome 
formation. Caspase-1 then cleaves proIL-1β into its mature, secreted form that mediates 
the inflammatory response. Pretreatment with lidocaine and Zep peptides 
downregulated expression of proIL-1β to attenuate IL-1β release. Cellular targets and 
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